Fulgent Genetics (Nasdaq:FLGT) - Stock Price, News & Analysis

FLGT Stock Overview

Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally.

FLGT fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	0/6
Past Performance	3/6
Financial Health	5/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (3.9x) is below the US market (15.1x)

Risk Analysis

Earnings are forecast to decline by an average of 68.7% per year for the next 3 years

Profit margins (33.8%) are lower than last year (55%)

Significant insider selling over the past 3 months

My Notes

New

Notes are coming soon

Fulgent Genetics, Inc. Competitors

DocGo

NasdaqCM:DCGO

US$1.0b

Cross Country Healthcare

NasdaqGS:CCRN

US$1.0b

National Research

NasdaqGS:NRC

US$1.1b

RadNet

NasdaqGM:RDNT

US$1.2b

Price History & Performance

Summary of all time highs, changes and price drops for Fulgent Genetics
Historical stock prices
Current Share Price	US$34.76
52 Week High	US$73.47
52 Week Low	US$28.53
Beta	1.58
1 Month Change	16.72%
3 Month Change	-12.29%
1 Year Change	-44.51%
3 Year Change	159.79%
5 Year Change	674.16%
Change since IPO	278.65%

Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)

Jan 15

Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

Dec 28

Recent updates

Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)

Jan 15

Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

Dec 28

What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates

Nov 16

Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency

Jun 04

These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely

May 04

Fulgent Genetics (NASDAQ:FLGT) Has A Rock Solid Balance Sheet

Jan 25

I Ran A Stock Scan For Earnings Growth And Fulgent Genetics (NASDAQ:FLGT) Passed With Ease

Dec 14

These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely

Oct 16

At US$85.24, Is Fulgent Genetics, Inc. (NASDAQ:FLGT) Worth Looking At Closely?

Sep 25

If You Like EPS Growth Then Check Out Fulgent Genetics (NASDAQ:FLGT) Before It's Too Late

Sep 07

Is Fulgent Genetics (NASDAQ:FLGT) A Risky Investment?

Jul 16

Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching

Jun 04

We Take A Look At Whether Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO May Be Underpaid

May 14

Shareholder Returns

	FLGT	US Healthcare	US Market
7D	6.5%	0.2%	2.8%
1Y	-44.5%	-0.2%	-9.2%

Return vs Industry: FLGT underperformed the US Healthcare industry which returned -0.2% over the past year.

Return vs Market: FLGT underperformed the US Market which returned -9.2% over the past year.

Price Volatility

Is FLGT's price volatile compared to industry and market?
FLGT volatility
FLGT Average Weekly Movement	7.1%
Healthcare Industry Average Movement	7.6%
Market Average Movement	6.9%
10% most volatile stocks in US Market	17.3%
10% least volatile stocks in US Market	2.8%

Stable Share Price: FLGT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: FLGT's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2011	645	Ming Hsieh	https://www.fulgentgenetics.com

Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2.

Fulgent Genetics, Inc. Fundamentals Summary

How do Fulgent Genetics's earnings and revenue compare to its market cap?
FLGT fundamental statistics
Market Cap	US$1.05b
Earnings (TTM)	US$271.57m
Revenue (TTM)	US$802.94m

3.9x

P/E Ratio

1.3x

P/S Ratio

Is FLGT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
FLGT income statement (TTM)
Revenue	US$802.94m
Cost of Revenue	US$259.48m
Gross Profit	US$543.45m
Other Expenses	US$271.88m
Earnings	US$271.57m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	8.99
Gross Margin	67.68%
Net Profit Margin	33.82%
Debt/Equity Ratio	1.6%

How did FLGT perform over the long term?

See historical performance and comparison

FLGT Stock Overview

Rewards

Risk Analysis

Fulgent Genetics, Inc. Competitors

NasdaqCM:DCGO

US$1.0b

NasdaqGS:CCRN

US$1.0b

NasdaqGS:NRC

US$1.1b

NasdaqGM:RDNT

US$1.2b

Price History & Performance

Recent News & Updates

Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)

Fulgent Genetics, Inc. Appoints Reggie Groves to Its Board of Directors

Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

Chief Financial Officer recently sold US$23k worth of stock

Fulgent Genetics, Inc., Annual General Meeting, May 01, 2023

Chief Financial Officer recently sold US$64k worth of stock

Recent updates

Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)

Fulgent Genetics, Inc. Appoints Reggie Groves to Its Board of Directors

Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

Chief Financial Officer recently sold US$23k worth of stock

Fulgent Genetics, Inc., Annual General Meeting, May 01, 2023

Chief Financial Officer recently sold US$64k worth of stock

What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates

Less than half of directors are independent

Fulgent Genetics, Inc. (NasdaqGM:FLGT) acquire Fulgent Pharma Holdings, Inc for approximately $100 million.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Fulgent Genetics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2022

Fulgent Genetics, Inc. Announces Resignation of Leonard Post from the Board and as the Chair of the Nominating and Corporate Governance Committee

Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching

The Klein Law Firm Files Class Action Complaint on Behalf of Shareholders of Fulgent Genetics, Inc

Fulgent Genetics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Less than half of directors are independent

Fulgent Genetics, Inc. Announces Resignation of John Bolger from the Board

Pomerantz Law Firm Announces the Filing of A Class Action Against Fulgent Genetics, Inc

We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending

Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly

Chief Financial Officer recently sold US$95k worth of stock

Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2022

Second quarter 2022 earnings released: EPS: US$0.38 (vs US$2.74 in 2Q 2021)

Fulgent Genetics, Inc. Announces Launch of PCR Based Test to Detect Monkeypox

Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement

Fulgent Genetics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Helio Genomics and Fulgent Genetics Announces That American Medical Association Approves A New Category I Cpt® Code for the Helioliver™ Test

Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency

Chief Financial Officer recently sold US$64k worth of stock

Price target decreased to US$91.00

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Fulgent Genetics, Inc. Provides Earning Guidance for Second Quarter of 2022

Fulgent Genetics, Inc. Announces Executive Appointments

These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely

Fulgent Genetics, Inc. Revises Revenue Guidance for the First Quarter Ended March 31, 2022 and Full Year Ended December 31, 2022

Fulgent Genetics, Inc., Annual General Meeting, May 18, 2022

Investor sentiment deteriorated over the past week

Independent Director exercised options and sold US$99k worth of stock

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Fulgent Genetics, Inc. Provides Earning Guidance for the First Quarter and Full Year of 2022

Fulgent Genetics, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Fulgent Genetics (NASDAQ:FLGT) Has A Rock Solid Balance Sheet

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

I Ran A Stock Scan For Earnings Growth And Fulgent Genetics (NASDAQ:FLGT) Passed With Ease

Chief Financial Officer recently sold US$52k worth of stock

Investor sentiment deteriorated over the past week

Chief Operating Officer recently sold US$61k worth of stock

Chief Financial Officer notifies of intention to sell stock

Chief Operating Officer recently sold US$116k worth of stock

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS US$4.13 (vs US$2.11 in 3Q 2020)

These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely

Price target increased to US$141

At US$85.24, Is Fulgent Genetics, Inc. (NASDAQ:FLGT) Worth Looking At Closely?

Chief Financial Officer recently sold US$57k worth of stock

If You Like EPS Growth Then Check Out Fulgent Genetics (NASDAQ:FLGT) Before It's Too Late